Stem Cells Clinical Trial
Official title:
Isolation and Characterization of Mammary Stem Cells
Verified date | March 23, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Cancer stem cells in breast cancer have been identified as a small population of tumor
cells whose self-renewal mechanism is highly deregulated. This deregulation seems to be
necessary for cancer to develop.
- These cells can be identified by certain surface markers that overlap with markers
associated with normal embryonic stem cells.
Objective: To isolate tumor stem cells using the same methods generally used to isolate human
embryonic stem cells.
Eligibility:
- Tissue samples will be obtained from the human cooperative network.
- Samples will include normal tissues from individuals who have no opportunistic diseases
and from individuals with cancer.
Design: Breast cancer stem cells will be isolated, grown in the laboratory and characterized.
Status | Completed |
Enrollment | 400 |
Est. completion date | March 23, 2011 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
- INCLUSION CRITERIA: The tissue samples will come from the human cooperative network. They have their own set of criteria. We are requesting tissue samples from individuals that are normal as well as those who have cancer. EXCLUSION CRITERIA: The tissue samples will come from the human cooperative tissue network and we are asking for normal samples from individuals who don't have any opportunistic diseases. |
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI), 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | National Institutes of Health (NIH) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Not yet recruiting |
NCT04998461 -
Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
|
||
Completed |
NCT04132531 -
Effect of Weight Loss Surgery on Stem Cells.
|
||
Completed |
NCT03381599 -
Stem Cells After Peripheral Mobilization and Harvest
|
Phase 1 | |
Completed |
NCT02697682 -
Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study
|
N/A | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Not yet recruiting |
NCT03361631 -
Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes
|
Phase 1 | |
Not yet recruiting |
NCT03983902 -
Placental Transfusion Methods and Stem Cells
|
N/A | |
Completed |
NCT06219161 -
The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.
|
N/A | |
Completed |
NCT04713436 -
The Effects of Antibiotic Combinations on Stem Cells
|
||
Active, not recruiting |
NCT03028428 -
Intra-articular Injection of MSCs in Treatment of Knee OA
|
Phase 2 | |
Recruiting |
NCT04646603 -
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
|
Phase 2 | |
Withdrawn |
NCT02677350 -
AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)
|
Phase 1 | |
Terminated |
NCT00316069 -
Stem Cell Collection
|